Excellent Q2 nos from Shilpa Medicare

Posted at October 21, 2009 written by Ayush

Shilpa Medicare (reviewed on July 26) has posted fantastic Q2 nos. Few highlights are:

I expect the company to continue posting such healthy nos and should better out in coming quarters. The stock has all the potential to move to the next orbit of Rs 250-300 levels.

Similar Posts:

Company Data

If you enjoyed this post, please consider to leave a comment or subscribe to the feed and get future articles delivered to your feed reader.

  • Dear Manmohan,

    As per my reading, Shilpa has posted excellent Q3 nos. I'm more than happy with the nos :)

    Stock might be down due to the fall in market and sentiment, leading to profit booking (stock has had a fantastic run up)

    Keep patience. If the company continues to maintain margins and grow like before, the stock should cross 300-350 levels also.

    Regards,
  • Manmohan
    Hi Ayush,

    What is wrong with Shilpa's Q3 numbers? The stock is hammered and is at 10% lower circuit.

    Also Vishnukant Bhutada, MD , Shilpa Med had mentioned in CNBC that they have patent molecules lined up till 2017 and will be able to maintain OPM.

    Regards,
    Manmohan
blog comments powered by Disqus